• Search
  • Advanced Search

Previous issues

  • HOME
  • BROWSE ARTICLES
  • Previous issue
Volume 29(2); Apr 2023
Reviews
1761
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
Clin Mol Hepatol. 2023;29(2):197-205.   Published online January 5, 2023
1755
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao
Clin Mol Hepatol. 2023;29(2):206-216.   Published online December 22, 2022
1758
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(2):217-229.   Published online December 28, 2022
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):230-241.   Published online January 30, 2023
1813
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(2):242-251.   Published online March 20, 2023
1797
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.   Published online March 10, 2023
1764
The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(2):263-276.   Published online January 19, 2023
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Clin Mol Hepatol. 2023;29(2):277-292.   Published online January 30, 2023
1769
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, Beatriz San-Miguel, María J. Tuñón, Javier González-Gallego, José L. Mauriz
Clin Mol Hepatol. 2023;29(2):293-319.   Published online February 1, 2023
1770
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):320-331.   Published online February 1, 2023
Editorials
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clin Mol Hepatol. 2023;29(2):332-334.   Published online March 16, 2023
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
Do Young Kim
Clin Mol Hepatol. 2023;29(2):335-338.   Published online March 20, 2023
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Shan Shan, Jidong Jia
Clin Mol Hepatol. 2023;29(2):339-341.   Published online March 16, 2023
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen
Clin Mol Hepatol. 2023;29(2):342-344.   Published online March 16, 2023
The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(2):345-348.   Published online March 9, 2023
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
Shen-Yung Wang
Clin Mol Hepatol. 2023;29(2):349-351.   Published online March 20, 2023
Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
San-Chi Chen
Clin Mol Hepatol. 2023;29(2):352-354.   Published online March 20, 2023
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):355-357.   Published online March 9, 2023
1802
The current trends in the health burden of primary liver cancer across the globe
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2023;29(2):358-362.   Published online March 14, 2023
1795
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee
Clin Mol Hepatol. 2023;29(2):363-366.   Published online March 9, 2023
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Joo Hyun Oh, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):367-370.   Published online March 20, 2023
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):371-373.   Published online March 14, 2023
The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clin Mol Hepatol. 2023;29(2):374-376.   Published online March 6, 2023
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol. 2023;29(2):377-380.   Published online March 9, 2023
Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
Heejoon Jang, Won Kim
Clin Mol Hepatol. 2023;29(2):381-383.   Published online March 9, 2023
Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2023;29(2):384-389.   Published online March 14, 2023
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Philipp Kasper, Münevver Demir, Hans-Michael Steffen
Clin Mol Hepatol. 2023;29(2):390-393.   Published online March 20, 2023
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clin Mol Hepatol. 2023;29(2):394-397.   Published online April 1, 2023
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Maamon Basheer, Mohamed Naffaa, Nimer Assy
Clin Mol Hepatol. 2023;29(2):398-400.   Published online February 13, 2023
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Kee-Huat Chuah, Wah-Kheong Chan
Clin Mol Hepatol. 2023;29(2):401-403.   Published online February 28, 2023
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
Clin Mol Hepatol. 2023;29(2):404-407.   Published online March 14, 2023
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Ji-Won Park, Ki Tae Suk
Clin Mol Hepatol. 2023;29(2):408-410.   Published online March 16, 2023
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):411-413.   Published online March 6, 2023
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clin Mol Hepatol. 2023;29(2):414-416.   Published online February 28, 2023
Original Articles
1772
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi
Clin Mol Hepatol. 2023;29(2):417-432.   Published online November 21, 2022
1760
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
Clin Mol Hepatol. 2023;29(2):433-452.   Published online January 4, 2023
1771
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol. 2023;29(2):453-464.   Published online February 1, 2023
1782
Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun
Clin Mol Hepatol. 2023;29(2):465-481.   Published online February 20, 2023
1763
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clin Mol Hepatol. 2023;29(2):482-495.   Published online January 5, 2023
1789
Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol. 2023;29(2):496-509.   Published online March 6, 2023
Letter to the Editor
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Chia-Ming Chu, Yun-Fan Liaw
Clin Mol Hepatol. 2023;29(2):510-512.   Published online January 30, 2023
Correspondence
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Jeong-Ju Yoo, Sang Gyune Kim
Clin Mol Hepatol. 2023;29(2):513-515.   Published online February 15, 2023
Snapshot
1783
Systemic therapy in advanced hepatocellular carcinoma
Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang
Clin Mol Hepatol. 2023;29(2):516-519.   Published online February 20, 2023

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1155
TOTAL : 2090475
Close layer